Anemia affects almost 1 in 4 people worldwide. But while billions of people live with the disease, its signs and symptoms aren’t just part of everyday life. “Anemia is one of the most common global ...
Shares of Akebia Therapeutics fell sharply premarket after it abandoned plans for a clinical trial of its anemia treatment in patients not on kidney dialysis following a meeting with the Food and Drug ...
The proposed trial aimed to study the use of vadadustat to treat anemia in patients with late-stage chronic kidney disease not on dialysis. The treatment is already approved for such patients who have ...
Clinical stage generative artificial intelligence (AI)-driven biotechnology company InSilico Medicine ("InSilico"), today announced that the Journal of Medicinal Chemistry, an ACS Publications journal ...
The iron deficiency anemia therapy market is propelled by the increasing cases of IDA, majorly in women, children, and the ...
Hypomethylating agents are standard in MDS treatment, with new drugs like Rytelo enhancing anemia management. Targeted therapies for IDH1/IDH2 mutations offer promising options, though challenges in ...
Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization ...
The development of new or worsening anemia did not decrease Jakafi’s efficacy in treating primary or secondary myelofibrosis. Patients with primary or secondary myelofibrosis who developed new or ...
Warm hemolytic anemia is a rare condition that affects your red blood cells. It causes anemia-like symptoms, such as fatigue, jaundice, and paleness. Share on Pinterest ZeynepKaya/Getty Images In warm ...
Studies show patients with chronic kidney disease (CKD) and COVID-19 are at increased risk for an intensive care unit stay and early death. Anemia is an extra risk factor.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback